3.355
4.83%
-0.165
2 Seventy Bio Inc stock is traded at $3.355, with a volume of 386.32K.
It is down -4.83% in the last 24 hours and down -32.87% over the past month.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$3.52
Open:
$3.53
24h Volume:
386.32K
Relative Volume:
1.27
Market Cap:
$176.12M
Revenue:
$44.12M
Net Income/Loss:
$-156.25M
P/E Ratio:
-0.8123
EPS:
-4.13
Net Cash Flow:
$-154.61M
1W Performance:
-27.17%
1M Performance:
-32.87%
6M Performance:
-30.21%
1Y Performance:
+57.28%
2 Seventy Bio Inc Stock (TSVT) Company Profile
Name
2 Seventy Bio Inc
Sector
Industry
Phone
339-499-9300
Address
60 BINNEY STREET, CAMBRIDGE
Compare TSVT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
TSVT | 3.355 | 176.12M | 44.12M | -156.25M | -154.61M | -4.13 |
VRTX | 467.43 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.66 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 565.62 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.53 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.40 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-13-23 | Downgrade | Goldman | Buy → Neutral |
Sep-12-23 | Downgrade | Guggenheim | Buy → Neutral |
Jul-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-31-22 | Initiated | Guggenheim | Buy |
May-02-22 | Initiated | Goldman | Buy |
Feb-10-22 | Initiated | SVB Leerink | Outperform |
Jan-06-22 | Initiated | Cowen | Outperform |
Nov-09-21 | Initiated | Canaccord Genuity | Buy |
Nov-08-21 | Initiated | Morgan Stanley | Overweight |
Nov-08-21 | Initiated | Wedbush | Outperform |
View All
2 Seventy Bio Inc Stock (TSVT) Latest News
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewswire
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference - Business Wire
2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Exchange Traded Concepts LLC - Defense World
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) - Yahoo Finance
Dimensional Fund Advisors LP Sells 24,371 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
BMS and 2seventy bio Axe Trial for Ide-Cel in Newly Diagnosed Multiple Myeloma - CGTLive™
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance - Business Wire
Seven Eight Capital LP Makes New $197,000 Investment in Beyond, Inc. (NYSE:BYON) - Defense World
Q&A: Athens legends Five Eight and the makers of their new documentary film, "Weirdo" - Online Athens
Four killed, dozens injured in Alabama mass shooting - Daily Sun
Seven Eight Capital LP Sells 536 Shares of Dell Technologies Inc. (NYSE:DELL) - Defense World
Four dead, 17 others shot in Birmingham mass shooting - WJLA
Five Below, Inc. (NASDAQ:FIVE) Stake Raised by Teca Partners LP - Defense World
Four killed, over 20 injured in Birmingham, Alabama shooting - Thaiger World
At least four dead and dozens injured in shootout with multiple assailants in the United States - Top Buzz Times
Four people dead and dozens injured in US mass shooting horror - Express
Analyst bullish on Tectonic's TX45 ahead of full trial results presentation at AHA - Investing.com India
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 - GlobeNewswire
Hedge fund Two Sigma in settlement talks with US SEC, WSJ reports - XM
US data: key federal and state updates (13 – 19 Sep) - Lexology
The LYCRA Company Presents Seminars on Sustainable Elastane Solutions at the 63rd Dornbirn Global Fiber Congress - Via Ritzau
Jessica Snow Sells 7,816 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock - Defense World
2seventy bio, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress - Business Wire
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024 - Business Wire
Biopharma Layoff Tracker 2024: Cue, Anokion, GlycoMimetics and More Cut Staff - BioSpace
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Royals select Florida 2-way star Caglianone 6th overall - theScore
Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff - BioSpace
2 Seventy Bio Inc Stock (TSVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):